Expert review of clinical pharmacology · 2026
Biosimilars for chronic plaque psoriasis: a 2026 update.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maurelli Martina, Danese Andrea, Gisondi Paolo, Girolomoni Giampiero
Аннотация
INTRODUCTION: Biosimilars have emerged as a key strategy to improve access to biologic therapies in moderate-to-severe psoriasis, addressing long-standing limitations related to treatment costs and availability.
AREAS COVERED: This narrative review summarizes the current evidence on biosimilars approved for psoriasis, including tumor necrosis factor inhibitors and ustekinumab, focusing on efficacy, safety, interchangeability, and pharmacoeconomic impact. A literature search was conducted in PubMed/MEDLINE and Embase to identify relevant clinical trials, real-world studies, and pharmacoeconomic analyses published between January 2015 and January 2026. Available data consistently demonstrate that biosimilars are highly similar to their reference biologics, with no clinically meaningful differences in efficacy, safety, or immunogenicity. Pharmacoeconomic studies across Europe confirm substantial cost savings and reduced cost-per-responder, supporting broader and earlier access to biologic therapy.
EXPERT OPINION: Biosimilars should be considered as first-line biologic options when appropriate, not only as cost-saving alternatives. Their wider use may enable earlier intervention, potentially reducing long-term disease burden and improving health system sustainability.
AREAS COVERED: This narrative review summarizes the current evidence on biosimilars approved for psoriasis, including tumor necrosis factor inhibitors and ustekinumab, focusing on efficacy, safety, interchangeability, and pharmacoeconomic impact. A literature search was conducted in PubMed/MEDLINE and Embase to identify relevant clinical trials, real-world studies, and pharmacoeconomic analyses published between January 2015 and January 2026. Available data consistently demonstrate that biosimilars are highly similar to their reference biologics, with no clinically meaningful differences in efficacy, safety, or immunogenicity. Pharmacoeconomic studies across Europe confirm substantial cost savings and reduced cost-per-responder, supporting broader and earlier access to biologic therapy.
EXPERT OPINION: Biosimilars should be considered as first-line biologic options when appropriate, not only as cost-saving alternatives. Their wider use may enable earlier intervention, potentially reducing long-term disease burden and improving health system sustainability.